Skip to main content

21-05-2019 | Respiratory | Video

ATS 2019: CFTR modulators impact immune cell function in cystic fibrosis

Benjamin Kopp discusses study findings demonstrating that CFTR modulator therapies have a differential impact on immune cell function depending on the agent used and the patient’s genotype, which has implications for clearing chronic airway infections in individuals with cystic fibrosis (3:25).

Funding for independent interviews at ATS 2019 was provided by F.Hoffmann-La Roche Ltd, Basel, Switzerland.